A tuberculosis that occurs at body sites other than the lung.
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation is limited for extrapulmonary tuberculosis primarily due to its rarity and the variability in how it presents across different patients. The condition affects fewer individuals compared to pulmonary tuberculosis, resulting in fewer systematic studies. Additionally, the diverse clinical manifestations can overlap with other diseases, complicating accurate characterization and understanding.
To navigate your care effectively, consider consulting an infectious disease specialist with experience in tuberculosis management. It may also be beneficial to connect with research institutions or hospitals that focus on tuberculosis treatment. Resources such as the Global Alliance for TB Drug Development (http://www.tballiance.org) can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to new therapies and comprehensive care options.
There are several FDA-approved treatments for extrapulmonary tuberculosis, including Pretomanid, Rifampin, Isoniazid, Pyrazinamide, and Rifapentine. Additionally, there are multiple orphan drugs in development, such as (R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole and others. Currently, there are 19 active clinical trials investigating various aspects of this condition. For more information, you can explore ongoing studies at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=extrapulmonary%20tuberculosis.
Actionable guidance for navigating care for extrapulmonary tuberculosis
To navigate your care effectively, consider consulting an infectious disease specialist with experience in tuberculosis management. It may also be beneficial to connect with research institutions or hospitals that focus on tuberculosis treatment. Resources such as the Global Alliance for TB Drug Development (http://www.tballiance.org) can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to new therapies and comprehensive care options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation is limited for extrapulmonary tuberculosis primarily due to its rarity and the variability in how it presents across different patients. The condition affects fewer individuals compared to pulmonary tuberculosis, resulting in fewer systematic studies. Additionally, the diverse clinical manifestations can overlap with other diseases, complicating accurate characterization and understanding.
To navigate your care effectively, consider consulting an infectious disease specialist with experience in tuberculosis management. It may also be beneficial to connect with research institutions or hospitals that focus on tuberculosis treatment. Resources such as the Global Alliance for TB Drug Development (http://www.tballiance.org) can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to new therapies and comprehensive care options.
There are several FDA-approved treatments for extrapulmonary tuberculosis, including Pretomanid, Rifampin, Isoniazid, Pyrazinamide, and Rifapentine. Additionally, there are multiple orphan drugs in development, such as (R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole and others. Currently, there are 19 active clinical trials investigating various aspects of this condition. For more information, you can explore ongoing studies at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=extrapulmonary%20tuberculosis.
Actionable guidance for navigating care for extrapulmonary tuberculosis
To navigate your care effectively, consider consulting an infectious disease specialist with experience in tuberculosis management. It may also be beneficial to connect with research institutions or hospitals that focus on tuberculosis treatment. Resources such as the Global Alliance for TB Drug Development (http://www.tballiance.org) can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to new therapies and comprehensive care options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation is limited for extrapulmonary tuberculosis primarily due to its rarity and the variability in how it presents across different patients. The condition affects fewer individuals compared to pulmonary tuberculosis, resulting in fewer systematic studies. Additionally, the diverse clinical manifestations can overlap with other diseases, complicating accurate characterization and understanding.
To navigate your care effectively, consider consulting an infectious disease specialist with experience in tuberculosis management. It may also be beneficial to connect with research institutions or hospitals that focus on tuberculosis treatment. Resources such as the Global Alliance for TB Drug Development (http://www.tballiance.org) can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to new therapies and comprehensive care options.
There are several FDA-approved treatments for extrapulmonary tuberculosis, including Pretomanid, Rifampin, Isoniazid, Pyrazinamide, and Rifapentine. Additionally, there are multiple orphan drugs in development, such as (R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole and others. Currently, there are 19 active clinical trials investigating various aspects of this condition. For more information, you can explore ongoing studies at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=extrapulmonary%20tuberculosis.
Actionable guidance for navigating care for extrapulmonary tuberculosis
To navigate your care effectively, consider consulting an infectious disease specialist with experience in tuberculosis management. It may also be beneficial to connect with research institutions or hospitals that focus on tuberculosis treatment. Resources such as the Global Alliance for TB Drug Development (http://www.tballiance.org) can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to new therapies and comprehensive care options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.